HazMat Fee + There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
| Type | HazMat fee for 500 gram (Estimated) |
| Excepted Quantity | USD 0.00 |
| Limited Quantity | USD 15-60 |
| Inaccessible (Haz class 6.1), Domestic | USD 80+ |
| Inaccessible (Haz class 6.1), International | USD 150+ |
| Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
| Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | STAT1 ↓ ↑ | STAT3 ↓ ↑ | STAT5 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nifuroxazide | ✔ | 98% | |||||||||||||||||
| Fludarabine | ✔ | 98% | |||||||||||||||||
| Artesunate | ✔ | 98% | |||||||||||||||||
| BP-1-102 |
+++
STAT3, Kd: 504 nM |
99%+ | |||||||||||||||||
| Niclosamide |
++
STAT3, IC50: 0.7 μM |
98% | |||||||||||||||||
| Napabucasin | ✔ | 98% | |||||||||||||||||
| Cryptotanshinone |
++
STAT3, IC50: 4.6 μM |
98% | |||||||||||||||||
| Stattic |
+
STAT3, IC50: 5.1 μM |
98% | |||||||||||||||||
| NSC 74859 |
+
STAT3, IC50: 86 μM |
99%+ | |||||||||||||||||
| Ochromycinone | ✔ | 98% | |||||||||||||||||
| HO-3867 | ✔ | 97% | |||||||||||||||||
| C188-9 |
++++
STAT3, Kd: 4.7 nM |
99%+ | |||||||||||||||||
| HJC0152 | ✔ | 99% | |||||||||||||||||
| SH5-07 | ✔ | 95% | |||||||||||||||||
| SH-4-54 |
++++
STAT3, Kd: 300 nM |
+++
STAT5, Kd: 464 nM |
99%+ | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | HO-3867, a curcumin analogue, is a selective STAT3 inhibitor. It selectively inhibited STAT3 phosphorylation, transcription, and DNA binding without affecting the expression of other active STATs at 10μM. HO-3867 significantly inhibited BRCA-mutated ovarian cancer cells expressing higher level of Tyrosine-phosphorylated STAT3 (pTyr705) in vitro, in a dose (1-20μM)- and time (12-48h)-dependent manner, with apoptosis shown by elevated levels of cleaved caspase-3, caspase-7 and PARP. Also, treatment with HO-3867 resulted in decreased expression of pTyr705 and its downstream targets cyclin D1, Bcl-2 and surviving in these cells. HO-3867 is a safe STAT3 Inhibitor for it exhibited minimal toxicity toward noncancerous cells and tissues but induced apoptosis in ovarian cancer cells. It inhibited cell migration/invasion and survival of primary human ovarian cancer cells isolated from patient ascites at 10μM post 24h. Administration of HO-3867 at 100ppm could block xenograft tumor growth without toxic side effects in nude mice injected with A2780 cells. |
| 作用机制 | HO-3867 has high affinity for a pocket located on the DNA-binding domain of the STAT3 and it could interact with both the STAT3 dimer and monomer structures.[1] |
| Concentration | Treated Time | Description | References | |
| CHO cells | 10 µM | 24 hours | HO-3867 exhibited minimal toxicity toward normal cells | Cancer Res. 2014 Apr 15;74(8):2316-27. |
| Ishikawa (IK) cells | 5 µM | 24 hours | Inhibition of EV secretion and EC cell proliferation | Oncogene. 2024 Nov;43(49):3586-3597. |
| Leishmania donovani promastigotes | 1-200 µg/ml | 2 hours | HO-3867 induced oxidative stress-mediated apoptosis in L. donovani promastigotes, characterized by altered cell morphology, phosphatidylserine externalization, mitochondrial depolarization, intracellular lipid accumulation, and cell cycle arrest. | Front Cell Infect Microbiol. 2021 Dec 3;11:774899. |
| Leishmania major promastigotes | 1-200 µg/ml | 2 hours | HO-3867 induced dose-dependent apoptosis in L. major promastigotes. | Front Cell Infect Microbiol. 2021 Dec 3;11:774899. |
| A2780 human epithelial ovarian cancer cells | 10 µM | 24 hours | To evaluate the inhibitory effect of HO-3867 on the STAT3 signaling pathway and its impact on cancer cell apoptosis. Results showed that HO-3867 significantly reduced the phosphorylation levels of STAT3 and induced apoptosis in cancer cells. | Free Radic Biol Med. 2010 May 1;48(9):1228-35. |
| HSMC human aortic smooth muscle cells | 10 µM | 24 hours | To evaluate the effect of HO-3867 on the viability of noncancerous cells. Results showed that HO-3867 was significantly less toxic to HSMC cells compared to cancer cells. | Free Radic Biol Med. 2010 May 1;48(9):1228-35. |
| OVTOKO cells | 5 µM and 10 µM | 24 hours | Treatment with HO-3867 decreased expression of pSTAT3 Tyr705 as well pSTAT3 Ser727, while total STAT3 remained constant. | Int J Cancer. 2017 Nov 1;141(9):1856-1866. |
| JHOC cells | 5 µM and 10 µM | 24 hours | Treatment with HO-3867 decreased expression of pSTAT3 Tyr705 as well pSTAT3 Ser727, while total STAT3 remained constant. | Int J Cancer. 2017 Nov 1;141(9):1856-1866. |
| A2780 cells | 10 µM | 24 hours | HO-3867 induced G2/M cell-cycle arrest in A2780 cells by modulating cell-cycle regulatory molecules p53, p21, p27, cdk2 and cyclin, and promoted apoptosis by caspase-8 and caspase-3 activation. | Mol Cancer Ther. 2010 May;9(5):1169-79. |
| SKOV3 cells | 10 µM | 24 hours | HO-3867 significantly inhibited the proliferation of SKOV3 cells and induced apoptosis. | Mol Cancer Ther. 2010 May;9(5):1169-79. |
| OVCAR3 cells | 10 µM | 24 hours | HO-3867 significantly inhibited the proliferation of OVCAR3 cells and induced apoptosis. | Mol Cancer Ther. 2010 May;9(5):1169-79. |
| U2OS cells | 2, 4, 8, 16, 32 µM | 24 hours | HO-3867 significantly reduced the viability of U2OS cells and induced apoptosis | Pharmaceutics. 2022 Jun 13;14(6):1257. |
| HOS cells | 2, 4, 8, 16, 32 µM | 24 hours | HO-3867 significantly reduced the viability of HOS cells and induced apoptosis | Pharmaceutics. 2022 Jun 13;14(6):1257. |
| MG-63 cells | 2, 4, 8, 16, 32 µM | 24 hours | HO-3867 significantly reduced the viability of MG-63 cells and induced apoptosis | Pharmaceutics. 2022 Jun 13;14(6):1257. |
| Ishikawa cells | 5 and 10 µM | 24 hours | HO-3867 significantly decreased the expression of pSTAT3 Ser727 while total STAT3 remained constant; cell viability decreased by 50–80% and induced G2/M arrest in 55% of Ishikawa cells at the G2/M cell cycle checkpoint. | Gynecol Oncol. 2014 Oct;135(1):133-41. |
| Human oral squamous cell carcinoma SCC-9 cells | 0, 2.5, 5, 10, and 20 µM | 24 hours | To evaluate the effect of HO-3867 on SCC-9 cell growth, results showed that HO-3867 effectively suppressed SCC-9 cell growth. | J Cell Mol Med. 2022 Apr;26(8):2273-2284. |
| Human oral squamous cell carcinoma HSC-3 cells | 0, 2.5, 5, 10, and 20 µM | 24 hours | To evaluate the effect of HO-3867 on HSC-3 cell growth, results showed that HO-3867 effectively suppressed HSC-3 cell growth. | J Cell Mol Med. 2022 Apr;26(8):2273-2284. |
| A195 cells | 10 µM | 24-72 hours | HO-3867 significantly suppressed the survival of A195 cells | Oncogene. 2017 Jan 12;36(2):168-181. |
| Ishikawa cells | 5 and 10 µM | 3 and 6 hours | HO-3867 selectively induced G2/M cell-cycle arrest in Ishikawa cells in a dose and time-dependent manner, with the greatest increase in G2/M cell population at 6 hours. | Gynecol Oncol. 2014 Oct;135(1):133-41. |
| A2780 cells | 10 µM | 3 hours | HO-3867 inhibited STAT3 nuclear translocation | Cancer Res. 2014 Apr 15;74(8):2316-27. |
| Human pulmonary artery smooth muscle cells | 0.5 µM and 1 µM | 48 and 72 hours | To study the effect of HO-3867 on peroxynitrite-induced cell proliferation, results showed that HO-3867 is capable of scavenging peroxynitrite and inhibiting peroxynitrite-induced smooth muscle cell proliferation. | Hypertension. 2013 Mar;61(3):593-601. |
| HUVEC cells | 5 µM and 10 µM | HO-3867 significantly inhibited formation of capillary-like structures and invasion in HUVEC cells. | Int J Cancer. 2017 Nov 1;141(9):1856-1866. | |
| Murine macrophages | 100 µg/ml | HO-3867 was completely safe for normal murine macrophages. | Front Cell Infect Microbiol. 2021 Dec 3;11:774899. | |
| Administration | Dosage | Frequency | Description | References | ||
| Rats | Left-heart failure-induced pulmonary hypertension model | Dietary administration | 100 ppm | Continued for 4 weeks | To study the effect of HO-3867 on left-heart failure-induced pulmonary hypertension, results showed that HO-3867 significantly attenuated the increase in pulmonary artery pressure and inhibited vascular remodeling by restoring PTEN activity. | Hypertension. 2013 Mar;61(3):593-601. |
| C57BL/6 mice | High-fat diet-induced endometrial hyperplasia model | Oral | 2 mg/kg | 8 weeks | Inhibition of high-fat diet-induced endometrial hyperplasia and EV secretion | Oncogene. 2024 Nov;43(49):3586-3597. |
| BALB/c Nude mice | Ovarian cancer xenograft model | Oral | 25, 50, 100 ppm | Once daily for 35 days | HO-3867 significantly inhibited the growth of the ovarian xenografted tumors in a dosage-dependent manner without any apparent toxicity. | Mol Cancer Ther. 2010 May;9(5):1169-79. |
| BALB/c Nude mice | Endometrial cancer xenograft model | Oral | 50 and 100 ppm | Continuous for 4 weeks | HO-3867 significantly inhibited the growth of xenograft endometrial tumors and induced apoptosis in vivo. | Gynecol Oncol. 2014 Oct;135(1):133-41. |
| Mice | Orthotopic ovarian cancer model | Oral | 50 and 100ppm | Once daily for 6 weeks | HO-3867 significantly suppressed ovarian tumor growth, angiogenesis, and metastasis | Oncogene. 2017 Jan 12;36(2):168-181. |
| Nude mice | A2780cDDP xenograft model | Oral | 50 or 100 ppm | 28 days | HO-3867 significantly inhibited tumor growth without toxic side effects | Cancer Res. 2014 Apr 15;74(8):2316-27. |
| Dose | Mice: 20 mg/kg[3] (i.v.) Rat: 10 mg/kg, 25 mg/kg[4] (i.p.) |
| Administration | i.v., i.p. |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
2.15mL 0.43mL 0.22mL |
10.76mL 2.15mL 1.08mL |
21.53mL 4.31mL 2.15mL |
|
| CAS号 | 1172133-28-6 |
| 分子式 | C28H30F2N2O2 |
| 分子量 | 464.55 |
| SMILES Code | O=C1/C(CN(CC2=CC(C)(C)N(O)C2(C)C)C/C1=C\C3=CC=C(F)C=C3)=C/C4=CC=C(F)C=C4 |
| MDL No. | MFCD28143913 |
| 别名 | |
| 运输 | 蓝冰 |
| InChI Key | PWZQFTQMMAIRRM-JFMUQQRKSA-N |
| Pubchem ID | 46871899 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Inert atmosphere, store in freezer, under -20°C |
| 溶解方案 |
DMSO: 30 mg/mL(64.58 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1